- Exchange: NYSE MKT LLC
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharma
Hemispherx Biopharma Inc+ Add to Watchlist
HEB:US0.2199 USD 0.0001 0.05%
As of 20:04:05 ET on 01/30/2015.
Company Profile for Hemispherx Biopharma Inc (HEB)
Hemispherx Biopharma, Inc. is a biopharmaceutical company that focuses on the development of nucleic acids to enhance the natural anti-viral defense systems of the human body. The Company's lead product, Ampligen, is undergoing clinical trials for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Hemispherx Biopharma Inc
Key Executives for Hemispherx Biopharma Inc (HEB)
|William A CarterChairman/Pres/CEO||Thomas K EquelsVice Chair/CFO/Secy/Gen Cnsl|
|David R StrayerChief Medical Ofcr/Medical Dir||Adam PascaleChief Accounting Officer|
|Wayne S SpringateSenior VP:Operations||Ralph Christopher CavalliVP:Quality Control|